ASCO: Impact of 2 New Drugs for the Treatment of Metastatic Melanoma

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Dr. Antoni Ribas, UCLA’s Jonsson Comprehensive Cancer Center and a presenter at this year’s annual meeting of the American Society of Clinical Oncology, discusses the impact of 2 new drugs- ipilimumab (Yervoy) and vemurafenib (Zelboraf)-for the treatment of metastatic melanoma.

Dr. Antoni Ribas, UCLA's Jonsson Comprehensive Cancer Center and a presenter at this year's annual meeting of the American Society of Clinical Oncology, discusses the impact of 2 new drugs- ipilimumab (Yervoy) and vemurafenib (Zelboraf)-for the treatment of metastatic melanoma.

Related Videos
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Experts on myeloma
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.
Related Content
Dabrafenib/Trametinib Yields Sustained Survival During Long-Term Follow-up in Advanced Melanoma

Dabrafenib/Trametinib Yields Sustained Survival During Long-Term Follow-up in Advanced Melanoma

Gina Mauro
June 1st 2024
Article

Continued survival was observed in dabrafenib/trametinib combination after 8 years follow-up in patients with advanced melanoma.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Oncology On-The-Go Podcast: ASCO 2023 Recap

Ritu Salani, MD;Tanios S. Bekaii-Saab, MD, FACP
June 19th 2023
Podcast

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Investigators may continue to reevaluate the benefits of the AI navigator MyEleanor over time in other patient populations.

AI Tool May Increase Colonoscopy Reengagement

Darlene Dobkowski, MA
May 24th 2024
Article

Investigators may continue to reevaluate the benefits of the AI navigator MyEleanor over time in other patient populations.

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

John M. Kirkwood, MD
April 8th 2022
Podcast

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.

Rates of HPV-related cancers may be decreased in patients under 40 have received an HPV vaccine.

HPV Vaccinations May Decrease HPV-Related Cancers in Those Under 40

Chris Ryan
May 23rd 2024
Article

Rates of HPV-related cancers may be decreased in patients under 40 have received an HPV vaccine.

The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.

Investigators Discontinue Vibostolimab Combo in Resected Melanoma Trial

Russ Conroy
May 14th 2024
Article

The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.